Literature DB >> 30713112

Tongue tremor in neurofascin-155 IgG4 seropositive chronic inflammatory polyradiculoneuropathy.

Chiara Briani1, Alessandro Salvalaggio2, Marta Ruiz2, Mario Cacciavillani3, Francesca Rinaldi2, Ilaria Callegari4, Roberto Gasparotti5, Diego Franciotta6.   

Abstract

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) with anti-neurofascin-155 antibodies is a subgroup of CIDP with tremor and poor response to intravenous immunoglobulins. A 23-year-old male presented with a 6-month history ataxic-stepping gait, stocking tactile hypoesthesia, areflexia, tremor at limbs and tongue. Neurophysiology and cerebrospinal fluid analysis supported the diagnosis of CIDP. Tongue EMG was negative. Serum was positive for neurofascin-155 IgG4. His symptoms improved with intravenous methylprednisolone and then immunoglobulins, but not the tremor. Neurofascin-155 antibodies binding to cerebellar neurons suggests its central origin. This is the first neurofascin-155 antibody-seropositive patient with also tongue tremor, who is candidate to rituximab.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP); Neurofascin-155; Tremor, tongue

Mesh:

Substances:

Year:  2019        PMID: 30713112     DOI: 10.1016/j.jneuroim.2019.01.017

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  3 in total

Review 1.  Distinguish CIDP with autoantibody from that without autoantibody: pathogenesis, histopathology, and clinical features.

Authors:  Lisha Tang; Qianyi Huang; Zhen Qin; Xiangqi Tang
Journal:  J Neurol       Date:  2020-04-07       Impact factor: 4.849

Review 2.  Neurofascin antibodies in chronic inflammatory demyelinating polyradiculoneuropathy: from intrinsic genetic background to clinical manifestations.

Authors:  Ze Wang; Xiajun Zhou; Nan Zhao; Chong Xie; Desheng Zhu; Yangtai Guan
Journal:  Neurol Sci       Date:  2021-03-29       Impact factor: 3.307

Review 3.  Efficacy of rituximab treatment in chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis.

Authors:  Jianian Hu; Chong Sun; Jiahong Lu; Chongbo Zhao; Jie Lin
Journal:  J Neurol       Date:  2021-06-12       Impact factor: 4.849

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.